ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint‐like inclusion body formation, and selective degeneration of dopaminergic neurons

[1]  R. Willemsen,et al.  The zebrafish homologue of Parkinson's disease ATP13A2 is essential for embryonic survival , 2013, Brain Research Bulletin.

[2]  E. Waxman,et al.  Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants , 2012, Journal of neuroscience research.

[3]  Sarah Sonnay,et al.  Common Pathogenic Effects of Missense Mutations in the P-Type ATPase ATP13A2 (PARK9) Associated with Early-Onset Parkinsonism , 2012, PloS one.

[4]  E. Bézard,et al.  Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration , 2012, Proceedings of the National Academy of Sciences.

[5]  V. Wong,et al.  Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity. , 2012, Human molecular genetics.

[6]  M. Duchen,et al.  Dopamine Induced Neurodegeneration in a PINK1 Model of Parkinson's Disease , 2012, PloS one.

[7]  J. Troncoso,et al.  PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. , 2012, Human molecular genetics.

[8]  D. Krainc,et al.  Deficiency of ATP13A2 Leads to Lysosomal Dysfunction, α-Synuclein Accumulation, and Neurotoxicity , 2012, The Journal of Neuroscience.

[9]  Zhuohua Zhang,et al.  Regulation of Intracellular Manganese Homeostasis by Kufor-Rakeb Syndrome-associated ATP13A2 Protein* , 2011, The Journal of Biological Chemistry.

[10]  C. van Broeckhoven,et al.  Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation. , 2011, Parkinsonism & related disorders.

[11]  J. Stockman.  Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease , 2011 .

[12]  R. Takahashi,et al.  Ammonium chloride and tunicamycin are novel toxins for dopaminergic neurons and induce Parkinson’s disease‐like phenotypes in medaka fish , 2010, Journal of neurochemistry.

[13]  R. Takahashi,et al.  Proteasome inhibition in medaka brain induces the features of Parkinson’s disease , 2010, Journal of neurochemistry.

[14]  S. Pappatà,et al.  Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability , 2010, neurogenetics.

[15]  A. Singleton,et al.  Early‐onset L‐dopa‐responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations , 2010, Movement disorders : official journal of the Movement Disorder Society.

[16]  Y. Sakaki,et al.  Loss of PINK1 in medaka fish (Oryzias latipes) causes late-onset decrease in spontaneous movement , 2010, Neuroscience Research.

[17]  R. Takahashi,et al.  A chemical neurotoxin, MPTP induces Parkinson's disease like phenotype, movement disorders and persistent loss of dopamine neurons in medaka fish , 2009, Neuroscience Research.

[18]  A. Brice,et al.  Parkinson's disease: from monogenic forms to genetic susceptibility factors. , 2009, Human molecular genetics.

[19]  R. Youle,et al.  Parkin is recruited selectively to impaired mitochondria and promotes their autophagy , 2008, The Journal of cell biology.

[20]  N. Hattori,et al.  PARK9-LINKED PARKINSONISM IN EASTERN ASIA: MUTATION DETECTION IN ATP13A2 AND CLINICAL PHENOTYPE , 2008, Neurology.

[21]  L. Thorne,et al.  Novel mutation and the first prenatal screening of cathepsin D deficiency (CLN10) , 2008, Acta Neuropathologica.

[22]  R. Marconi,et al.  ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease , 2007, Neurology.

[23]  T. Gasser.  Update on the genetics of Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[24]  Y. Sakaki,et al.  Generation of medaka gene knockout models by target-selected mutagenesis , 2006, Genome Biology.

[25]  Jan Gründemann,et al.  Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase , 2006, Nature Genetics.

[26]  P. Saftig,et al.  Cathepsin D deficiency is associated with a human neurodegenerative disorder. , 2006, American journal of human genetics.

[27]  A. Lehesjoki,et al.  Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. , 2006, Brain : a journal of neurology.

[28]  Z. Lukacs,et al.  Mutation of the glycosylated asparagine residue 286 in human CLN2 protein results in loss of enzymatic activity. , 2004, Glycobiology.

[29]  Jeremy N. Skepper,et al.  α-Synuclein Is Degraded by Both Autophagy and the Proteasome* , 2003, Journal of Biological Chemistry.

[30]  A. Barzilai,et al.  The molecular mechanisms of dopamine toxicity. , 2003, Advances in neurology.

[31]  David Blum,et al.  Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease , 2001, Progress in Neurobiology.

[32]  H. Nakanishi,et al.  Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[33]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[34]  A. Mubaidin,et al.  Pallido‐pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor‐Rakeb syndrome , 1994, Acta neurologica Scandinavica.

[35]  M. Baumann,et al.  Storage of saposins A and D in infantile neuronal ceroid‐lipofuscinosis , 1993, FEBS letters.

[36]  M. Idoate,et al.  Fabry's disease without angiokeratomas showing unusual eccrine gland vacuolation , 1992, Journal of Pathology.

[37]  J. Walker,et al.  Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease). , 1992, American journal of medical genetics.

[38]  K. Jellinger,et al.  Adult GM2 gangliosidosis masquerading as slowly progressive muscular atrophy: motor neuron disease phenotype. , 1982, Clinical neuropathology.